This company has been acquired
HZNP Stock Overview
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Horizon Therapeutics Public Limited Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$116.30 |
| 52 Week High | US$116.38 |
| 52 Week Low | US$60.03 |
| Beta | 1.01 |
| 1 Month Change | 0.76% |
| 3 Month Change | 12.37% |
| 1 Year Change | 82.80% |
| 3 Year Change | 45.18% |
| 5 Year Change | 505.10% |
| Change since IPO | 1,171.04% |
Recent News & Updates
Recent updates
Horizon pays HemoShear milestone payment under pact to develop gout therapies
Sep 21Horizon Therapeutics announces $500M buyback program
Sep 09Horizon Therapeutics to expand footprint in Ireland
Aug 29Horizon Therapeutics: This Core Biotech Company Is On Sale
Aug 19Horizon Therapeutics: Buy The Dip For Slightly Risky, Catalyst Driven Growth
Jul 31Horizon gets FDA approval for Krystexxa's use with methotrexate for uncontrolled gout
Jul 08Shareholder Returns
| HZNP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.06% | 5.0% | 0.5% |
| 1Y | 82.8% | -11.6% | 11.1% |
Return vs Industry: HZNP exceeded the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: HZNP exceeded the US Market which returned 14.1% over the past year.
Price Volatility
| HZNP volatility | |
|---|---|
| HZNP Average Weekly Movement | 2.0% |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: HZNP has not had significant price volatility in the past 3 months.
Volatility Over Time: HZNP's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 2,190 | Tim Walbert | www.horizontherapeutics.com |
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use.
Horizon Therapeutics Public Limited Company Fundamentals Summary
| HZNP fundamental statistics | |
|---|---|
| Market cap | US$26.63b |
| Earnings (TTM) | US$438.00m |
| Revenue (TTM) | US$3.64b |
Is HZNP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HZNP income statement (TTM) | |
|---|---|
| Revenue | US$3.64b |
| Cost of Revenue | US$824.98m |
| Gross Profit | US$2.82b |
| Other Expenses | US$2.38b |
| Earnings | US$438.00m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.91 |
| Gross Margin | 77.36% |
| Net Profit Margin | 12.02% |
| Debt/Equity Ratio | 48.2% |
How did HZNP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/10 07:33 |
| End of Day Share Price | 2023/10/05 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Horizon Therapeutics Public Limited Company is covered by 24 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Donald Ellis | Avondale Partners |
| Gary Nachman | BMO Capital Markets Equity Research |
| Jason Matthew Gerberry | BofA Global Research |